• English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • italiano 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Login
Mostra Item 
  •   DSpace Home
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Mostra Item
  •   DSpace Home
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Mostra Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
Tutto DSpace
  • Archivi & Collezioni
  • Data di pubblicazione
  • Autori
  • Titoli
  • Soggetti

Use of lincomycin to control respiratory infections in lambs: Effects on health and production

Thumbnail
Autore
Skoufos, J.; Mavrogianni, V. S.; Tzora, A.; Mavrommatis, I.; Alexopoulos, C.; Fthenakis, G. C.
Data
2006
DOI
10.1016/j.smallrumres.2005.09.006
Soggetto
sheep
atypical pneumonia
Mycoplasma spp.
lincomycin
antimicrobial
susceptibility
ANTIMICROBIAL SUSCEPTIBILITY
MYCOPLASMA-OVIPNEUMONIAE
PASTEURELLA-HAEMOLYTICA
VIRULENT FOOTROT
PNEUMONIA
SHEEP
TILMICOSIN
EFFICACY
FEED
SPECTINOMYCIN
Agriculture, Dairy & Animal Science
Mostra tutti i dati dell'item
Abstract
The efficacy of lincomycin to control respiratory infections in lambs was assessed in two trials. In trial 1, 72 lambs with active mycoplasmal pneumonia were allocated as follows: lambs in group T2 were treated with lincomycin (5 mg kg(-1) bodyweight, intramuscularly) twice 2 days apart, those in group T3 with lincomycin (5 mg kg(-1) bodyweight, intramuscularly) thrice with 2-day intervals, those in group O with oxytetracycline (20 mg kg(-1) bodyweight, intramuscularly) twice 4 days apart and those in group C were controls. In trial II, 48 25-30-day-old clinically healthy lambs were allocated as follows: lambs in group P2 received two injections of lincomycin (5 mg kg(-1) bodyweight, intramuscularly) when 30- and 60-day-old, lambs in group P1/30 received one injection of lincomycin (5 mg kg(-1) bodyweight, intramuscularly) when 30-day-old, lambs in group P1/60 received one injection of lincomycin (5 mg kg(-1) bodyweight, intramuscularly) when 60-day-old and lambs in group C were controls. In trial 1, treatment with lincomycin was associated with improved clinical scores; clinical cure rate 42 days after treatment was 87%, 100%, 87% and 0% for group T2, T3, 0 and C, respectively (P < 0.001); treated lambs produced 18.5% (T2) or 26.5% (T3) heavier carcass than controls; no lung lesions were seen in group T3 lambs, whilst they were evident in 22% of group T2 or group 0 lambs and in 72% of control lambs; microorganisms were isolated from lung tissue samples of 5 group C and I group 0 lambs. In trial 11, administration of lincomycin was associated with smaller clinical scores; prevalence rate of respiratory disorders at the end of the trial was 17%, 42%, 42% and 58% for group P2, P 1 /30, PI/60 and C, respectively (P < 0.01); treated lambs were > 4.5% heavier than controls; lung lesions were recorded in I group P2, 2 group P 1 /30 and group P1/60 and 5 group C lambs; microorganisms were isolated from I group P2, 3 group P 1 /30, 2 group PI/60 and 5 group C lambs. It is concluded that administration of lincomycin is effective for the treatment and the prevention of mycoplasmal atypical pneumonia in lambs. (c) 2005 Elsevier B.V. All rights reserved.
URI
http://hdl.handle.net/11615/33087
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [19734]
htmlmap 

 

Ricerca

Tutto DSpaceArchivi & CollezioniData di pubblicazioneAutoriTitoliSoggettiQuesta CollezioneData di pubblicazioneAutoriTitoliSoggetti

My Account

LoginRegistrazione
Help Contact
DepositionAboutHelpContattaci
Choose LanguageTutto DSpace
EnglishΕλληνικά
htmlmap